Atea Pharmaceuticals, Inc.: directors' dealings · United States · SEC (Form 4)

About Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) is a U.S.-based clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, United States. Founded in 2012, Atea focuses on discovering, developing, and commercializing oral antiviral therapeutics for serious viral diseases. The company has built its strategy around proprietary medicinal chemistry, virology expertise, and antiviral drug-development capabilities, targeting pathogens where there remains meaningful unmet medical need. As a late-stage biotech, Atea is not a commercial pharmaceutical company in the traditional sense; its value proposition is driven primarily by clinical execution, regulatory milestones, and the eventual translation of data into a potential approved product. Atea’s lead program is the fixed-dose combination of bemnifosbuvir and ruzasvir for chronic hepatitis C virus (HCV). Bemnifosbuvir is a nucleotide analog NS5B polymerase inhibitor, while ruzasvir is an NS5A inhibitor. The company is running a global Phase 3 development program consisting of two studies: C-BEYOND in North America and C-FORWARD outside North America. Based on the latest company disclosures, C-BEYOND is fully enrolled with more than 880 patients and topline results are expected in mid-2026, while C-FORWARD is expected to complete enrollment in mid-2026 with topline data anticipated around year-end 2026. If the program is successful, Atea is targeting a U.S. FDA NDA submission in March 2027. For investors, these readouts are the key near-term value inflection points. In 2025 and 2026, Atea also expanded its antiviral pipeline into hepatitis E virus (HEV). In January 2026, the company selected AT-587 as its lead HEV development candidate, with clinical development expected to begin in mid-2026. This is strategically relevant because HEV remains an underserved indication, particularly in immunocompromised patients, and there is currently no approved antiviral therapy. Atea has also reported encouraging preclinical data for AT-587 and related candidates, reinforcing the company’s ambition to build a broader hepatitis-focused antiviral franchise beyond HCV. Competitively, Atea operates in a field where established HCV treatments from larger pharmaceutical companies set a high bar for efficacy, safety, treatment duration, and convenience. Accordingly, Atea is positioning bemnifosbuvir/ruzasvir as a potentially best-in-class oral regimen with short duration, low drug-drug interaction risk, and practical dosing characteristics. The company’s geographic footprint remains centered in the United States, with its base in Boston and clinical trials spanning North America and other regions. Recent news flow has been dominated by Phase 3 enrollment progress, positive scientific presentations, and the extension of the pipeline into HEV. For French-speaking investors, Atea is a U.S. NASDAQ-listed biotech with a clearly catalyst-driven profile and meaningful clinical upside, but also substantial regulatory and execution risk typical of the sector.